INDP
Price
$0.84
Change
+$0.02 (+2.44%)
Updated
Mar 11, 01:57 PM (EDT)
Capitalization
9.85M
2 days until earnings call
ORMP
Price
$2.63
Change
+$0.12 (+4.78%)
Updated
Mar 11, 03:02 PM (EDT)
Capitalization
103.6M
78 days until earnings call
Ad is loading...

INDP vs ORMP

Header iconINDP vs ORMP Comparison
Open Charts INDP vs ORMPBanner chart's image
Indaptus Therapeutics
Price$0.84
Change+$0.02 (+2.44%)
Volume$100
Capitalization9.85M
Oramed Pharmaceuticals
Price$2.63
Change+$0.12 (+4.78%)
Volume$400
Capitalization103.6M
INDP vs ORMP Comparison Chart
Loading...
INDP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INDP vs. ORMP commentary
Mar 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INDP is a Buy and ORMP is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Mar 11, 2025
Stock price -- (INDP: $0.82 vs. ORMP: $2.52)
Brand notoriety: INDP and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INDP: 98% vs. ORMP: 81%
Market capitalization -- INDP: $9.85M vs. ORMP: $103.6M
INDP [@Biotechnology] is valued at $9.85M. ORMP’s [@Biotechnology] market capitalization is $103.6M. The market cap for tickers in the [@Biotechnology] industry ranges from $383.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INDP’s FA Score shows that 1 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • INDP’s FA Score: 1 green, 4 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, both INDP and ORMP are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INDP’s TA Score shows that 5 TA indicator(s) are bullish while ORMP’s TA Score has 4 bullish TA indicator(s).

  • INDP’s TA Score: 5 bullish, 3 bearish.
  • ORMP’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, INDP is a better buy in the short-term than ORMP.

Price Growth

INDP (@Biotechnology) experienced а +4.86% price change this week, while ORMP (@Biotechnology) price change was +26.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.73%. For the same industry, the average monthly price growth was -9.34%, and the average quarterly price growth was -8.76%.

Reported Earning Dates

INDP is expected to report earnings on May 08, 2025.

ORMP is expected to report earnings on May 28, 2025.

Industries' Descriptions

@Biotechnology (-0.73% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORMP($104M) has a higher market cap than INDP($9.85M). ORMP YTD gains are higher at: 4.132 vs. INDP (-2.624). ORMP has higher annual earnings (EBITDA): 9.44M vs. INDP (-15.37M). ORMP has more cash in the bank: 142M vs. INDP (7.38M). INDP has less debt than ORMP: INDP (108K) vs ORMP (429K). INDP (0) and ORMP (0) have equivalent revenues.
INDPORMPINDP / ORMP
Capitalization9.85M104M9%
EBITDA-15.37M9.44M-163%
Gain YTD-2.6244.132-64%
P/E RatioN/A22.91-
Revenue00-
Total Cash7.38M142M5%
Total Debt108K429K25%
FUNDAMENTALS RATINGS
INDP vs ORMP: Fundamental Ratings
INDP
ORMP
OUTLOOK RATING
1..100
1186
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
69
Overvalued
PROFIT vs RISK RATING
1..100
92100
SMR RATING
1..100
9781
PRICE GROWTH RATING
1..100
7494
P/E GROWTH RATING
1..100
10036
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INDP's Valuation (30) in the null industry is somewhat better than the same rating for ORMP (69) in the Pharmaceuticals Other industry. This means that INDP’s stock grew somewhat faster than ORMP’s over the last 12 months.

INDP's Profit vs Risk Rating (92) in the null industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that INDP’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's SMR Rating (81) in the Pharmaceuticals Other industry is in the same range as INDP (97) in the null industry. This means that ORMP’s stock grew similarly to INDP’s over the last 12 months.

INDP's Price Growth Rating (74) in the null industry is in the same range as ORMP (94) in the Pharmaceuticals Other industry. This means that INDP’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's P/E Growth Rating (36) in the Pharmaceuticals Other industry is somewhat better than the same rating for INDP (100) in the null industry. This means that ORMP’s stock grew somewhat faster than INDP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INDPORMP
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 14 days ago
79%
Bullish Trend 5 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 9 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
INDP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
POWW1.39-0.01
-0.71%
AMMO
AKAM84.14-3.39
-3.87%
Akamai Technologies
CNOB22.97-1.01
-4.21%
ConnectOne Bancorp
USM61.80-3.29
-5.05%
United States Cellular Corp
AIM0.13-0.01
-5.26%
AIM ImmunoTech

INDP and

Correlation & Price change

A.I.dvisor tells us that INDP and AFMD have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INDP and AFMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INDP
1D Price
Change %
INDP100%
-0.61%
AFMD - INDP
31%
Poorly correlated
-6.76%
SLNO - INDP
30%
Poorly correlated
-2.46%
VKTX - INDP
30%
Poorly correlated
-3.92%
ORMP - INDP
29%
Poorly correlated
-1.95%
AXON - INDP
28%
Poorly correlated
-2.08%
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with BTAI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then BTAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
-1.95%
BTAI - ORMP
44%
Loosely correlated
-12.31%
INO - ORMP
44%
Loosely correlated
-0.26%
MBIO - ORMP
44%
Loosely correlated
+1.35%
VERV - ORMP
44%
Loosely correlated
-11.33%
ZNTL - ORMP
43%
Loosely correlated
-1.92%
More